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Poster Session II S319Introduction:Transplant outcome is poor in patients with advanced
hematologic malignancies that are not in remission. We evaluated
the safety and efficacy of a preparative regimen consisting of frac-
tionated TBI (12 Gy) and MEL (100 mg/m2 in a single dose) in 26
adult patients with refractory/relapsed AML (n 5 11), ALL (n 5
5), NHL (n 5 5), and other malignancies (n 5 5) who received
allo-SCT between 2003 and 2008.
Patients and Methods:Median age was 49 (21 to 68) years and the
median time from initial diagnosis to allo-SCT was 12.8 months
(range, 2.3 to 58.8 months). Five patients had prior autologous
SCT and 3 had prior allo-SCT. At the time of transplant, 15
(58%) had poor-risk complex cytogenetics, 10 out of 16 acute leuke-
mia patients (63%) had circulating blasts. The stem cell product was
T-cell replete in all but one patient. Thirteen patients (50%) re-
ceived 8/8 matched MUD allo-SCT, 3 of whom were mismatched
at one antigen or allele level. Four patients received a bone marrow
product. Tacrolimus6 low dose methotrexate were used as GVHD
prophylaxis in the majority of patients.
Results: One patient died on day +7 after SCT. The remaining 25
patients achieved hematopoietic engraftment with no significant de-
lay. Treatment-related toxicity was moderate and consisted mainly
of mucositis, infections and pulmonary complications such as
CMV pneumonitis and diffuse alveolar hemorrhage. Three addi-
tional patients died early after SCT on days +32, +40 and +50. Me-
dian duration of hospitalization was 29 days (range, 14 to 97). Of
23 evaluable patients, 13 (57%) achieved complete remission (CR)
and 7 had partial remission. Three patients had no response to trans-
plant. Fourteen patients relapsed at a median time of 166 days (range
33-1548) after allo-SCT.Median overall survival of the entire group
was 159 days. The 3-year Kaplan-Meier estimate of survival for all 26
patients was 16%. One AML patient relapsed with a different clone
after remaining in CR for 4.9 years. Two patients are currently alive
and in CR at 995 and 1320 days posttransplant.
Conclusions: Our early data suggest that, TBI-MEL is an active
preparative regimen against acute leukemia and perhaps other ad-
vanced hematologic malignancies that are not in remission. Regi-
men-related toxicity is acceptable and relapse is the most common
cause of treatment failure. A comparative analysis in a larger data-
set is warranted to further evaluate the efficacy and safety of TB-
MEL in such high-risk patients.
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SERUM FERRITIN IS A POTENTIAL PROGNOSTIC MARKER FOR TREAT-
MENT-RELATED MORTALITY AND OVERALL SURVIVAL IN ALLOGENEIC
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In the past years, the roles of iron overloading in allogeneic hema-
topoietic stem trasnplnatation (allo-HSCT) had been discussed. Sev-
eral articles indicated that high serum ferritin level was a poor
prognostic marker, but this was not validated in Chinese population.
We then established a cohort of 101 patients who received allo-
HSCT in our hospital, one of the largest in Taiwan, from Jan,
2008 to Jul, 2010, and try to find if serum ferritin has any prognostic
significance for them.Theirmedian age was 32 y/o (0-61 y/o). Serum
ferritin was all checked within one month before allo-HSCT (me-
dian 1692 mg/dl, ranging from 56 to 23026 mg/dl), and patients
were grouped to high ferrtin group (ferritin . 1500 ng/ml, N 5
56) and low ferritin group (ferritin # 1500 mg/dl, N 5 45) accord-
ingly. Table 1 summerized the baseline characters of these 2 patient
groups. Almost all parameters were comparable, except that there
were a little more acute lymphoblastic leukemia patients in the low
ferritin group. After tranplant, the engraftment kinetics in high fer-
ritin group were comparable as those in low ferritin group (neutro-
phil recovery (ANC $ 0.5x109/L) 13.063.2 vs 13.666.7 days;
platelet recovery ($ 50x109/L) 25.6610.8 vs 28.6612.7 day). The
incidences of acute GVHD were also comparable (22/17 vs 18/20,
p 5 0.45). However, trends of increased 1-year treatment-related
mortality were observed in high ferritin group (26.267.8% vs
14.964.8%, p 5 0.064) and then 1-year overall survival was signifi-cantly compromised in high ferritin group (62.868.5% vs
79.265.8%, p 5 0.033). Relapse-free survival in high ferritin group
seemed to be lower, but not yet statistically different from that in
low-ferritin group (55.4612.4% vs 83.764.8%, p 5 0.113). From
this analysis, we can conclude that in Chinese population, patients
with serum ferritin$ 1500 mg/dl are at higher risk of treatment-re-
lated mortality and compromised overall survival when they receive
allo-HSCT. However, because serum ferrtin not only is affected by
body iron store but also is an indicator of systemic inflammation,
whether iron cheletion therapy would benifit these patients remains
unknown andwell-designed prospective clinical trials are still needed
for the answer.
Table 1. Comparison of the baseline characters of patients
with serum level#1500mg/dL and >1500mg/dL
Ferritin#1500mg/dL Ferritin>1500mg/dLPatient number 45 56
Age 26(0-61) 29(2-61)
Sex(M/F) 24/21 30/26
Cell Source
BM/PB/UCB 10/34/1 8/46/2
Donor
Sibling/Unrelated 31/15 34/22
Diagnosis
AML/ALL/CML 12/12/2 25/7/1
MPD or MDS 5 8
Lymphoma 7 4
Others 7 11
MNC(x10^8/Kg) 9.30 ± 7.39 9.57 ± 6.55
CD34+(x10^6/Kg) 5.67 ± 3.90 5.81 ± 4.24
Conditioning regimens
BuCy+/2ATG 17 19
TBI+Cy+/2ATG 8 8
F+Bu2y1+/2ATG 8 17
F+TBI+/2ATG 1 4
Others 11 8ATG, anti-thymocyte globulin; F, fludarbine; TBI, total body irradiation;
UCB, umbilical cord blood.
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Decitabine is effective for myelodysplastic syndrome but is not cu-
rative. The only curative treatment is allogeneic stem cell transplanta-
tion(allo-SCT). There were few reports about pretransplant use of
decitabine as a bridging therapy. We report 18 patients (median age
47, range 40-55 years, male 11, female 7) with MDS (9 patients were
in IPSS Int-1, 6 patients in Int-2, and 3 patients in IPSS high) who
all received at least 3 cycles of decitabine (median 4 cycles, range
38 cycles) and subsequent allo-SCT(from sibling donor in 5 patients,
unrelated donor in 13). Conditioning regimens consisted of FluBu46
ATGor low doseTBI400cGy (n5 8), FluBu2/ATG (n5 7), BuCY6
ATG (n5 2), or TBI/CY/ATG (n5 1). The source of stem cells was
marrow in 1 patients and peripheral blood in 17 patients. Successful
leukocyte engraftment was attained in 17/18 patients (median 12
days, range 917 days). Platelet engraftment was attained in 15/18 pa-
tients (median 15 days, range 1131 days). Grade IIIV skin acute
GVHD were in 5/18 patients, liver or gut acute GVHD in 1/18 pa-
tients. 14/18 patients achieved a CR at 30 days after transplant. Grade
IIIV chronic GVHD were in 10 patients. With a median follow-up
of 18 months (range, 628 months), 11 patients are alive with CR. 7
patients have died either from relapse (n 5 3) or treatment related
complications (n5 4).Responders to decitabinebefore transplantation
tend to have a better survival than non-responders. We conclude that
pretransplant use of decitabine is feasible, with no increased toxicity
and tend to improve the outcome of allo-SCT for MDS and should
be evaluated in a prospective trial.
